Trial Profile

Phase 1 single ascending dose study of SBT8230 in healthy volunteers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SBT 8230 (Primary)
Indications Hepatitis B
Focus Adverse reactions
Sponsors ARS Pharmaceuticals; Silverback Therapeutics

Most Recent Events

12 May 2022 According to Silverback Therapeutics media release, the company is on track to complete a regulatory submission in the fourth quarter of 2022. The company is expects to open enrollment for the single ascending dose healthy volunteer cohort in the first quarter of 2023 and anticipates reporting data from this portion of the study in the second half of 2023.
07 Apr 2022 New trial record
31 Mar 2022 According to Silverback Therapeutics media release, the company plans to open enrollment for this Phase 1 study of SBT8230 in healthy volunteers in the first half of 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com